Investing.com - Aridis Pharma (NASDAQ: ARDS) reported third quarter EPS of $-0.470, $0.30 worse than the analyst estimate of $-0.170. Revenue for the quarter came in at $399K...
By Sam Boughedda Investing.com — Aridis Pharmaceuticals Inc (NASDAQ:ARDS) shares have rallied Tuesday morning. The rise is a result of news that the company's antibody cocktail...
Aridis Pharmaceuticals, Inc. (OTC:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening...
Aridis Pharmaceuticals, Inc. (Nasdaq: NASDAQ:ARDS) today announced positive feedback from the European Medicines Agency (EMA) on the Company’s proposed single confirmatory Phase 3...
Aridis Pharmaceuticals, Inc. (Nasdaq: NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating...
Aridis Pharmaceuticals, Inc. (Nasdaq: NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating...
Aridis Pharmaceuticals, Inc. (Nasdaq: NASDAQ:ARDS) today announced positive feedback from the FDA on the Company’s proposed single confirmatory Phase 3 study of investigational...
Aridis Pharmaceuticals, Inc. (Nasdaq: NASDAQ:ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, announced today that it received a notice (the “Notice”) from the...
Aridis Pharmaceuticals, Inc. (Nasdaq: NASDAQ:ARDS), a biopharmaceutical company, today announced that it has entered into a definitive agreement for the issuance and sale of an...